Among the patients treated with lenvatinib, in the univariate analysis, modified G8 score (≤10 vs. ≥11: HR0.31; 95% CI 0.11–0.89; p = .029), intrahepatic tumor volume (<50% vs. ≥50%: HR 13.6; 95% CI, 2.19–84.3; p = .0051), DCP (<400 vs. ≥400: HR 4.99; 95% CI 1.36–18.3; p = .015), and AFP(<400 vs. ≥400: HR 4.61; 95% CI 1.37–15.5; p = .013) were associated with OS. The gene discussed is AFP; the disease is neoplasm.